News & Trends - MedTech & Diagnostics
Cutting-edge medical technology in advanced cancer therapy

MedTech News: When Lynne Norton received the devastating news her cancer had not only returned, but spread to her brain and bones, she faced the prospect of having only months to live.
Cutting-edge radiation therapy from Varian’s HyperArc technology reduced her treatment to less than a week, with few side-effects, and gave her hope of a brighter future.
Associate Professor Matthew Foote, a radiation oncologist at Greenslopes Private Hospital, was instrumental in bringing the technology to Australia.
“HyperArc is helping us redefine how we manage people with advanced cancer. The reality is that if secondary tumours aren’t treated aggressively and quickly, the chances of being alive in six months are very low,” he said.
“It delivers a higher dose of radiation directly to the tumours with a relatively low impact on quality of life. We’ve continued to improve functionality of this technology, and we are now treating up to 18 brain lesions at a time, something unheard of 10 years ago. A significant proportion of patients with a diagnosis like Lynne are now living far beyond 12 months.”
The new technology can treat multiple brain tumours in minutes with one automated setup, while limiting radiation doses to surrounding healthy brain tissue.
“Cancer is becoming a chronic disease with more and more people living longer with advanced disease,” A/Prof Foote said.
“Unfortunately recurrence of cancers in the brain continue to rise but with these cutting-edge developments in treatment we are able to help people with secondary cancers who would otherwise have very few options.”
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More